CSL222_3003 - NCT05962398 - Enrolling by invitation

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B

• Key Inclusion: Received treatment with CSL222 in Study CSL222_2001 or Study CSL222_3001, and completed participation in Study CSL222_2001 or Study CSL222_3001 or at least 5 years have passed since receiving CSL222.
• Key Exclusion: None

Principle Investigator: Bradley Fletcher, MD, PhD

C0371017 - NCT05568719 - Recruiting

A Phase 3, Non-Investigational Product, Multi-Country Cohort Study to Describe the Long-Term Safety and Effectiveness of a Prior Single-Dose Treatment with Investigative Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Participants with Hemophilia A or Hemophilia B, Respectively.

• Key Inclusion: Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.

• Key Exclusion: None

Principle Investigator: Bradley Fletcher, MD, PhD

CDC Community Counts - Actively Enrolling

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

• Key Inclusion: People who receive care at HTCs are eligible to participate in Community Counts if they have been diagnosed with a bleeding disorder. Their condition must be present since birth and must be one of the following bleeding disorders:
  • Hemophilia A (classic hemophilia/hereditary factor VVI [8] deficiency)
  • Hemophilia B (Christmas disease/hereditary factor IX [9] deficiency)
  • Von Willerbrand Disease
  • Certain rare clotting factor disorders and platelet disorders
• Key Exclusion: None

Principle Investigator: Bradley Fletcher, MD, PhD